Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Linagliptin”

Showing 20 of 0 results

Not applicableUnknownNCT06098625
What this trial is testing

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

Who this might be right for
Diabetes MellitusKidney Transplant; Complications
Medanta, The Medicity, India 200
Early research (Phase 1)Not Yet RecruitingNCT07034781
What this trial is testing

Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

Who this might be right for
Type2 Diabetes Mellitus
AJU Pharm Co., Ltd. 50
Large-scale testing (Phase 3)Study completedNCT01087502
What this trial is testing

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 241
Large-scale testing (Phase 3)Study completedNCT01215097
What this trial is testing

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 306
Large-scale testing (Phase 3)Study completedNCT00654381
What this trial is testing

Japanese P III vs Voglibose and Placebo

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 561
Post-approval studies (Phase 4)Looking for participantsNCT06862739
What this trial is testing

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

Who this might be right for
Diabetes MellitusType 2 DM
Nabiqasim Industries (Pvt) Ltd 800
Early research (Phase 1)Study completedNCT01581931
What this trial is testing

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Who this might be right for
Healthy
Boehringer Ingelheim 32
Large-scale testing (Phase 3)Study completedNCT00996658
What this trial is testing

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 278
Post-approval studies (Phase 4)Study completedNCT02467478
What this trial is testing

Linagliptin's Effect on CD34+ Stem Cells

Who this might be right for
Type 2 DiabetesImpaired Renal Function
George Washington University 31
Post-approval studies (Phase 4)Study completedNCT01512979
What this trial is testing

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 316
Early research (Phase 1)Study completedNCT02084082
What this trial is testing

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Who this might be right for
Healthy
Boehringer Ingelheim 68
Large-scale testing (Phase 3)Study completedNCT00736099
What this trial is testing

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 2,122
Early research (Phase 1)Study completedNCT02180503
What this trial is testing

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Who this might be right for
Healthy
Boehringer Ingelheim 24
Large-scale testing (Phase 3)Ended earlyNCT01888796
What this trial is testing

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus

Who this might be right for
Diabetes Mellitus Type 2 (T2DM)Left Ventricular Diastolic Dysfunction
RWTH Aachen University 8
Post-approval studies (Phase 4)Enrolling By InvitationNCT07452913
What this trial is testing

Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
Bahria University 110
Early research (Phase 1)Study completedNCT02220647
What this trial is testing

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 96
Post-approval studies (Phase 4)Study completedNCT02061969
What this trial is testing

ADA Linagliptin in Long Term Care

Who this might be right for
Diabetes
Emory University 140
Testing effectiveness (Phase 2)Study completedNCT01012037
What this trial is testing

Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Who this might be right for
Diabetes Mellitus, Type 2
Boehringer Ingelheim 491
Post-approval studies (Phase 4)Study completedNCT03194945
What this trial is testing

Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes

Who this might be right for
Type 2 Diabetes Mellitus
Sun Yat-sen University 412
Not applicableStudy completedNCT03970668
What this trial is testing

Linagliptin in Post-renal Transplantation

Who this might be right for
Transplanted Kidney Complication
Universidad de Guanajuato 28
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation